All Stories

  1. Hemispheric lateralization of dopamine transporter binding in Parkinson's disease
  2. Idiopathic polyneuropathy with neurogenic autonomic failure – an early manifestation of Lewy body disease? a case report
  3. Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder
  4. Inter-relationship of the age of onset to the concept of brain-first versus body-first Parkinson's disease
  5. Myocardial sympathetic distal axon loss in subjects with Lewy pathology in three autopsy cohorts
  6. Trusting Your Gut When it Comes to the Origin of Parkinson's Disease
  7. Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder
  8. Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson’s disease
  9. Impaired sleep microarchitecture is associated with locus coeruleus degeneration in Parkinson’s disease
  10. Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease
  11. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals
  12. The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
  13. Impact of norepinephrine versus phenylephrine on brain circulation, organ blood flow and tissue oxygenation in anaesthetised patients with brain tumours: study protocol for a randomised controlled trial
  14. Bradykinesia and postural instability in a model of prodromal synucleinopathy with α-synuclein aggregation initiated in the gigantocellular nuclei
  15. Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms
  16. Validation of a data-driven motion-compensated PET brain image reconstruction algorithm in clinical patients using four radiotracers
  17. Non-motor asymmetry and dopamine degeneration in Parkinson’s disease
  18. Cuneus atrophy and Parkinsonian phenoconversion in cognitively unimpaired patients with isolated REM sleep behavior disorder
  19. Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy
  20. Cholinergic dysfunction in isolated rapid eye movement sleep behaviour disorder links to impending phenoconversion
  21. Correlation between dopaminergic and metabolic asymmetry in Lewy body disease – A dual-imaging study
  22. Approaches to Early Parkinson’s Disease Subtyping
  23. Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”
  24. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
  25. Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same
  26. The Body, the Brain, the Environment, and Parkinson’s Disease
  27. Functional and 123I-MIBG scintigraphy assessment of cardiac adrenergic dysfunction in diabetes
  28. Microglial Activation and Progression of Nigrostriatal Dysfunction in Isolated REM Sleep Behavior Disorder
  29. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease
  30. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes
  31. Brain-first vs. body-first Parkinson's disease: An update on recent evidence
  32. Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies
  33. STING activation counters glioblastoma by vascular alteration and immune surveillance
  34. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder
  35. Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies
  36. Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
  37. Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease
  38. The heterogeneity of Parkinson’s disease
  39. The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models
  40. Distribution of cholinergic nerve terminals in the aged human brain measured with [18F]FEOBV PET and its correlation with histological data
  41. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases : An [ 11 C ] UCB‐J ...
  42. Thyroid [123I]MIBG uptake in Parkinson’s disease and diabetes mellitus
  43. Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies
  44. Cholinergic Imaging and Dementia
  45. Disruption of Sleep Microarchitecture Is a Sensitive and Early Marker of Parkinson’s Disease
  46. Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study
  47. RBDtector: an open-source software to detect REM sleep without atonia according to visual scoring criteria
  48. Revisiting the Dual-Hit Hypothesis: Insights from Postmortem Studies in Parkinson's Disease
  49. [18F]FEOBV positron emission tomography may not be a suitable method to measure parasympathetic denervation in patients with Parkinson's disease
  50. Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
  51. Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up
  52. Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial
  53. Impact of aging on animal models of Parkinson's disease
  54. Intestinal Transit in Early Moderate Parkinson’s Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate
  55. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
  56. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  57. In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study
  58. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
  59. Passive Immunization in Alpha-Synuclein Preclinical Animal Models
  60. Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
  61. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  62. Neuropathological evidence of body-first vs. brain-first Lewy body disease
  63. Long-term Risk of Parkinson Disease Following Influenza and Other Infections
  64. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes
  65. Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts
  66. Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy
  67. Radionuclide imaging of the gut-brain axis in Parkinson’s disease
  68. Cortical Activity During an Attack of Ménière's Disease—A Case Report
  69. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease
  70. Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study
  71. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  72. Fasting gallbladder volume is increased in patients with Parkinson's disease
  73. Preserved noradrenergic function in Parkinson's disease patients with rest tremor
  74. Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
  75. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
  76. Prodromal Parkinson disease subtypes — key to understanding heterogeneity
  77. Impaired cerebral microcirculation in isolated REM sleep behaviour disorder
  78. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline
  79. Asymmetric Distribution of Dopamine Transporters in Premorbid Corticobasal Syndrome—A Case Report
  80. Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
  81. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder
  82. The Logic and Pitfalls of Parkinson's as Brain‐ Versus Body‐First Subtypes
  83. Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson’s disease
  84. Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ
  85. Gastrointestinal Dysfunction in Parkinson’s Disease
  86. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder
  87. Abstract
  88. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study
  89. Absent 18F-FDG Uptake in the Brain—Unsuspected Brain Death
  90. Skin Temperature in Parkinson’s Disease Measured by Infrared Thermography
  91. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms
  92. Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study
  93. A Screening-Based Method for Identifying Patients with REM Sleep Behaviour Disorder in a Danish Community Setting
  94. Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
  95. Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson’s disease to healthy controls
  96. Normative values for gastric motility assessed with the 3D‐transit electromagnetic tracking system
  97. PET Visualized Stimulation of the Vestibular Organ in Menière's Disease
  98. Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
  99. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder
  100. In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients
  101. Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis
  102. Enteric cholinergic neuropathy in patients with diabetes: Non‐invasive assessment with positron emission tomography
  103. Normative values for region‐specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D‐Transit electromagnet tracking system: Influence of age, gender, and body mass index
  104. Positron emission tomography visualized stimulation of the vestibular organ is localized in Heschl's gyrus
  105. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
  106. Engineered antibodies: new possibilities for brain PET?
  107. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats
  108. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas
  109. Cardiac 11C-Donepezil Binding Increases With Age in Healthy Humans: Potentially Signifying Sigma-1 Receptor Upregulation
  110. The Gut and Parkinson’s Disease: Hype or Hope?
  111. Imaging the Autonomic Nervous System in Parkinson’s Disease
  112. Evaluation of Active Brown Adipose Tissue by the Use of Hyperpolarized [1-13C]Pyruvate MRI in Mice
  113. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study
  114. Objective intestinal function in patients with idiopathic REM sleep behavior disorder
  115. Is constipation in Parkinson's disease caused by gut or brain pathology?
  116. The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer’s Disease
  117. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder
  118. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study
  119. Preclinical evaluation of potential infection-imaging probe [68 Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation
  120. Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury
  121. Gastric emptying in Parkinson's disease – A mini-review
  122. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients
  123. F26. Automated chin EMG analysis for quantification of REM sleep without atonia
  124. Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm
  125. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease
  126. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study
  127. Multimodal 18 F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma
  128. Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study
  129. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
  130. Pancreatic Polypeptide in Parkinson’s Disease: A Potential Marker of Parasympathetic Denervation
  131. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study
  132. Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER
  133. How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology
  134. Gastrointestinal Transit Time in Parkinson’s Disease Using a Magnetic Tracking System
  135. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease
  136. Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson’s Disease: A Colon Transit and Volume Study
  137. Preventing Parkinson disease by vagotomy
  138. Imaging Parkinson’s disease below the neck
  139. Reply to the letter to the Editor: Comment to Barichella and colleagues
  140. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography
  141. Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy
  142. Decreased intestinal acetylcholinesterase in early Parkinson disease
  143. Kinetic Modelling of Infection Tracers [18F]FDG, [68Ga]Ga-Citrate, [11C]Methionine, and [11C]Donepezil in a Porcine Osteomyelitis Model
  144. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives
  145. Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV
  146. Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up
  147. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study
  148. Vagotomy and subsequent development of diabetes – A nested case–control study
  149. A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis
  150. In vivoimaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
  151. Imaging Systemic Dysfunction in Parkinson’s Disease
  152. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
  153. Sex differences of human cortical blood flow and energy metabolism
  154. Does vagotomy reduce the risk of Parkinson's disease: The authors reply
  155. Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI
  156. EANM’15
  157. Reply
  158. Pseudoprogression after proton radiotherapy for pediatric low grade glioma
  159. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging
  160. Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV
  161. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease
  162. Vagotomy and subsequent risk of Parkinson's disease
  163. Olfactory function in Parkinson's Disease - effects of training
  164. Salivary Acetylcholinesterase Activity Is Increased in Parkinson’s Disease: A Potential Marker of Parasympathetic Dysfunction
  165. Imaging the parasympathetic nervous system in Parkinson's disease
  166. In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using 11C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses
  167. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders
  168. False-Positive 123I-FP-CIT Scintigraphy and Suggested Dopamine Transporter Upregulation Due to Chronic Modafinil Treatment
  169. Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
  170. Cerebral oxygen metabolism in patients with early Parkinson's disease
  171. Clinical heterogeneity in Parkinson’s disease revisited: a latent profile analysis
  172. Glucose metabolism in small subcortical structures in Parkinson’s disease
  173. Odor identification deficits identify Parkinson's disease patients with poor cognitive performance
  174. The Parkinsonian Personality and Concomitant Depression
  175. Molecular Imaging and the Neuropathologies of Parkinson’s Disease
  176. Variable ATP Yields and Uncoupling of Oxygen Consumption in Human Brain
  177. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages
  178. Partial volume correction using cortical surfaces
  179. Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study
  180. A deformation-based morphometry study of patients with early-stage Parkinson’s disease
  181. Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization
  182. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization
  183. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson’s disease
  184. Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy
  185. Improvement of brain tissue oxygenation by inhalation of carbogen
  186. Effect of memantine on CBF and CMRO2in patients with early Parkinson’s disease
  187. Normalization in PET group comparison studies—The importance of a valid reference region
  188. Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease